Curated News
By: NewsRamp Editorial Staff
September 17, 2024
BioMed X and Ono Pharmaceutical Co., Ltd. Collaborate on New Immunotherapy Research Team
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- BioMed X and Ono Pharmaceutical Co., Ltd. collaborate to investigate antitumor effects of neutrophils for next-generation immunotherapies.
- The new research team at the BioMed X Institute in Heidelberg, Germany, will focus on understanding neutrophil biology and developing effective cancer therapies.
- The research undertaken by the new team aims to pave the way for the development of groundbreaking treatments, potentially improving the lives of cancer patients.
- The presence of neutrophils in solid tumors has been well-documented, although their role in the tumor microenvironment seems paradoxical according to current data.
Impact - Why it Matters
This news matters as it highlights the collaboration between BioMed X and Ono Pharmaceutical to conduct groundbreaking research on next-generation immunotherapies, offering potential breakthroughs in cancer treatment. The partnership may lead to the development of more effective therapies for cancer patients, impacting the future of cancer treatment.
Summary
BioMed X, a German biomedical research institute, has announced a new research team at the BioMed X Institute in Heidelberg, Germany, in partnership with Ono Pharmaceutical Co., Ltd. The joint research project aims to investigate the antitumor effects of neutrophils to develop next-generation immunotherapies. The team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany, and two research groups overseas.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, BioMed X and Ono Pharmaceutical Co., Ltd. Collaborate on New Immunotherapy Research Team
